Mayne Pharma Group Limited
MAYNF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $390 | $456 | $375 | $507 |
| - Cash | $60 | $54 | $110 | $109 |
| + Debt | $41 | $40 | $70 | $37 |
| Enterprise Value | $371 | $442 | $335 | $434 |
| Revenue | $195 | $213 | $200 | $188 |
| % Growth | -8.5% | 6.3% | 6.7% | – |
| Gross Profit | $116 | $131 | $113 | $74 |
| % Margin | 59.7% | 61.4% | 56.4% | 39.5% |
| EBITDA | $18 | $25 | $23 | -$110 |
| % Margin | 9% | 11.5% | 11.7% | -58.8% |
| Net Income | -$68 | -$26 | -$104 | -$71 |
| % Margin | -35% | -12% | -51.7% | -37.5% |
| EPS Diluted | -0.89 | -0.25 | -1.24 | -0.87 |
| % Growth | -256% | 79.8% | -42.5% | – |
| Operating Cash Flow | $30 | -$13 | $13 | -$25 |
| Capital Expenditures | -$5 | -$7 | -$5 | -$16 |
| Free Cash Flow | $25 | -$20 | $9 | -$41 |